Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cisplatin + cyclophosphamide + etoposide + vinblastine + vincristine
- Development stage
- Unknown
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of six anticancer agents: doxorubicin (an anthracycline), cisplatin (a platinum compound), cyclophosphamide (an alkylating agent), etoposide (a topoisomerase inhibitor), vinblastine and vincristine (both vinca alkaloids). This multi-agent therapy is used in the treatment of various cancers, particularly small cell lung cancer. The combination works through multiple mechanisms to target rapidly dividing cancer cells.
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))MicrotubuleTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + cisplatin + cyclophosphamide + etoposide + vinblastine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cisplatin + cyclophosphamide + etoposide + vinblastine + vincristine.